Bronchial thermoplasty in patients with dynamic hyperinflation: results from the proof-of-concept HEAT trial

International audienceSevere refractory asthma affects 3–5% of asthmatic patients, but represents 50–80% of asthma-related healthcare costs [1]. Although therapies targeting IgE and, more recently, IL5 and IL4/13 have recently gained approval for the treatment of severe refractory asthma in a subset of patients with type 2 phenotypes, there is still a need to cover a wider range of patients, in particular those with a non-type 2 phenotype or for whom biotherapies faile